BioXcel Therapeutics, Inc. (BTAI)
NASDAQ$2.25
Market Cap
$7.39M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
496 of 924
Rank in Industry
287 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BTAI Insider Trading Activity
BTAI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $457,050 | 29 | 100 |
Related Transactions
| O'Neill Vincent | See Remarks | 0 | $0 | 5 | $3,841 | $-3,841 |
| Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | 0 | $0 | 4 | $6,562 | $-6,562 |
| Rodriguez Javier | See Remarks | 0 | $0 | 4 | $7,136 | $-7,136 |
| Yocca Frank | Chief Scientific Officer | 0 | $0 | 5 | $7,630 | $-7,630 |
| Steinhart Richard I | Chief Financial Officer | 0 | $0 | 5 | $7,685 | $-7,685 |
| Mehta Vimal | CEO and President | 0 | $0 | 6 | $424,195 | $-424,195 |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the …
Insider Activity of BioXcel Therapeutics, Inc.
Over the last 12 months, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $457,050 worth of BioXcel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $27.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,108 shares for transaction amount of $14,514 was made by MUELLER PETER (director) on 2019‑08‑23.
List of Insider Buy and Sell Transactions, BioXcel Therapeutics, Inc.
| 2024-12-16 | Sale | Mehta Vimal | CEO and President | 3,117 0.0062% | $0.36 | $1,131 | -21.38% | |
| 2024-12-16 | Sale | Yocca Frank | Chief Scientific Officer | 430 0.0008% | $0.35 | $152 | -21.38% | |
| 2024-12-16 | Sale | Steinhart Richard I | Chief Financial Officer | 577 0.0011% | $0.36 | $207 | -21.38% | |
| 2024-12-16 | Sale | O'Neill Vincent | See Remarks | 165 0.0003% | $0.35 | $58 | -21.38% | |
| 2024-10-03 | Sale | Yocca Frank | Chief Scientific Officer | 7,175 0.0181% | $0.55 | $3,946 | -28.75% | |
| 2024-10-03 | Sale | Rodriguez Javier | See Remarks | 6,863 0.0173% | $0.55 | $3,775 | -28.75% | |
| 2024-10-03 | Sale | Steinhart Richard I | Chief Financial Officer | 7,175 0.0181% | $0.55 | $3,946 | -28.75% | |
| 2024-10-03 | Sale | O'Neill Vincent | See Remarks | 5,556 0.014% | $0.55 | $3,056 | -28.75% | |
| 2024-10-03 | Sale | Wiley Matthew T. | Chief Commercial Officer | 6,272 0.0158% | $0.55 | $3,450 | -28.75% | |
| 2024-09-16 | Sale | Mehta Vimal | CEO and President | 1,982 0.0052% | $0.69 | $1,367 | -36.04% | |
| 2024-09-16 | Sale | Yocca Frank | Chief Scientific Officer | 355 0.0009% | $0.69 | $245 | -36.04% | |
| 2024-09-16 | Sale | Rodriguez Javier | See Remarks | 345 0.0009% | $0.69 | $238 | -36.04% | |
| 2024-09-16 | Sale | Steinhart Richard I | Chief Financial Officer | 356 0.0009% | $0.69 | $246 | -36.04% | |
| 2024-09-16 | Sale | Wiley Matthew T. | Chief Commercial Officer | 215 0.0006% | $0.69 | $149 | -36.04% | |
| 2024-09-16 | Sale | O'Neill Vincent | See Remarks | 138 0.0004% | $0.69 | $95 | -36.04% | |
| 2024-06-17 | Sale | Mehta Vimal | CEO and President | 2,134 0.0051% | $1.28 | $2,739 | -57.47% | |
| 2024-06-17 | Sale | Yocca Frank | Chief Scientific Officer | 372 0.0009% | $1.28 | $476 | -57.47% | |
| 2024-06-17 | Sale | Rodriguez Javier | See Remarks | 361 0.0008% | $1.26 | $456 | -57.47% | |
| 2024-06-17 | Sale | Steinhart Richard I | Chief Financial Officer | 372 0.0009% | $1.26 | $470 | -57.47% | |
| 2024-06-17 | Sale | O'Neill Vincent | See Remarks | 155 0.0004% | $1.28 | $199 | -57.47% |
Total: 81
*Gray background shows transactions not older than one year
Insider Historical Profitability
94.37%
| Mehta Vimal | CEO and President | 59605 1.8116% | $133,813.23 | 9 | 12 | +91.12% |
| Yocca Frank | Chief Scientific Officer | 28931 0.8793% | $64,950.10 | 5 | 10 | +91.88% |
| Steinhart Richard I | Chief Financial Officer | 20932 0.6362% | $46,992.34 | 3 | 8 | +87.62% |
| MUELLER PETER | director | 168320 5.1158% | $377,878.40 | 6 | 0 | +104.84% |
| Nandabalan Krishnan | 0 0% | $0 | 1 | 5 | +93.45% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,253,997 | 122 | -53.40% | $10.96M | |
$1,159,104 | 40 | -21.75% | $8.25M | |
BioXcel Therapeutics, Inc. (BTAI) | $523,320 | 24 | 94.37% | $7.39M |
$746,223 | 23 | -7.24% | $8.9M | |
$31,129 | 22 | -11.96% | $5.92M |
BTAI Institutional Investors: Active Positions
| Increased Positions | 17 | +23.61% | 362,290 | +184.94% |
| Decreased Positions | 29 | -40.28% | 22,426 | -11.45% |
| New Positions | 8 | New | 275,240 | New |
| Sold Out Positions | 11 | Sold Out | 6,181 | Sold Out |
| Total Postitions | 60 | -16.67% | 535,757 | +173.49% |
BTAI Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Armistice Capital, Llc | $583.00 | 8.99% | 269,688 | +269,688 | New | 2024-12-31 |
| Ubs Group Ag | $172.00 | 2.66% | 79,806 | +78,979 | +9,550.06% | 2024-12-31 |
| Vanguard Group Inc | $160.00 | 2.47% | 74,217 | -869 | -1.16% | 2024-12-31 |
| Blackrock, Inc. | $51.00 | 0.79% | 23,788 | +1,133 | +5% | 2024-12-31 |
| Geode Capital Management, Llc | $42.00 | 0.65% | 19,498 | +870 | +4.67% | 2024-12-31 |
| Wells Fargo & Company/Mn | $27.00 | 0.42% | 12,438 | +872 | +7.54% | 2024-12-31 |
| Millennium Management Llc | $14.00 | 0.22% | 6,561 | -1,487 | -18.48% | 2024-12-31 |
| Renaissance Technologies Llc | $11.00 | 0.16% | 4,869 | -3,248 | -40.02% | 2024-12-31 |
| State Street Corp | $10.00 | 0.16% | 4,822 | 0 | 0% | 2024-12-31 |
| Northern Trust Corp | $10.00 | 0.15% | 4,619 | +2,072 | +81.35% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.